Lannett Company, Inc. FDA Inspection Record
Lannett Company, Inc. is an FDA-inspected facility (FEI 2510865) located in Philadelphia, PA, US. RegDataLab tracks 10 FDA inspections and 1 compliance action at this facility.
What FDA found at this site
- Latest inspection
- Mar 25, 2022: No Action Indicated (NAI)
- Inspections on record
- 10 (5 VAI, 5 NAI)
- Last OAI inspection
- None on record
- Warning letters
- 1 listed by FDA for this FEI, latest Mar 30, 2009
- Recalls as the recalling firm
- 7, latest Feb 9, 2022
- Import refusals
- 3
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Mar 25, 2022 | No Action Indicated (NAI) | No citations listed |
| Jan 25, 2019 | No Action Indicated (NAI) | No citations listed |
| Jun 22, 2017 | No Action Indicated (NAI) | No citations listed |
| Sep 16, 2016 | Voluntary Action Indicated (VAI) | No citations listed |
| Aug 6, 2013 | No Action Indicated (NAI) | No citations listed |
| Aug 17, 2012 | Voluntary Action Indicated (VAI) | No citations listed |
| Mar 21, 2011 | Voluntary Action Indicated (VAI) | Buildings of Suitable Size, Construction, Location (21 CFR 211.42(a)) Defined areas of adequate size for operations (21 CFR 211.42(c)) Written procedures not established/followed (21 CFR 211.67(b)) Absence of Written Procedures (21 CFR 211.100(a)) and 3 more |
| Sep 14, 2010 | No Action Indicated (NAI) | No citations listed |
| Feb 9, 2010 | Voluntary Action Indicated (VAI) | Absence of Written Procedures (21 CFR 211.100(a)) Rejected Material Area (21 CFR 211.42(c)(2)) Investigations of discrepancies, failures (21 CFR 211.192) Extent of discrepancy, failure investigations (21 CFR 211.192) and 4 more |
| Feb 9, 2010 | Voluntary Action Indicated (VAI) | No citations listed |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Feb 9, 2022 | Class II | D-0558-2022 | Diazepam Oral Solution (Concentrate), 25 mg per 5 mL (5 mg/mL), 30 mL BOTTLE and DROPPER… Failed Impurities/Degradation Specifications: Out of specification results for related substances. |
| Aug 10, 2020 | Class II | D-1508-2020 | Prednisone Tablets, USP 2.5 mg, 100 tablets, Rx only, Distributed by: Lannett Company… Labeling: Label Mix Up: bottle labeled to contain Prednisone Tablets, USP 2.5 mg actually contained Prednisone Tablets, USP 10 mg |
| Dec 6, 2019 | Class I | D-0630-2020 | Levetiracetam Oral Solution 100mg/mL, 473 mL (16 fl. oz.) Bottles, Rx Only, Distributed… Microbial Contamination of Non-sterile Products: Out-of-specification results obtained for Total Aerobic Microbial Count. |
| Oct 28, 2019 | Class II | D-0309-2020 | Lannett Ranitidine Syrup (Ranitidine Oral Solution, USP), 15mg/mL Rx Only Distributed by… CGMP Deviations: Presence of NDMA impurity detected in product. |
| Oct 11, 2018 | Class II | D-0083-2019 | HydrOXYzine HYDROCHLORIDE SYRUP (HydrOXYzine Hydrochloride Oral Solution, USP), 10 mg per… CGMP Deviations: cleaning procedures during manufacturing caused out of specification results for unknown impurities. |
| Jan 27, 2010 | Class II | D-357-2010 | Dipyridamole Tablets, USP 25 mg, 100 and 1000 count bottles, Rx Only, Manufactured by… Failed USP dissolution test requirements |
| Nov 10, 2003 | Class III | D-078-4 | Butalbital, Aspirin, and Caffeine Capsules, (50 mg Butalbital, 325 mg Aspirin, 40 mg… ANDA/NDA Discrepancies: Manufacturing process used an unapproved source of butalbital |
FDA record score
9 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
12 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Class I recall D-0630-2020, this FEI as the recalling firm | Dec 6, 2019 | 15 x 0.25 | 3.8 |
| Class II recall D-0558-2022, this FEI as the recalling firm | Feb 9, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-1508-2020, this FEI as the recalling firm | Aug 10, 2020 | 4 x 0.25 | 1 |
| Class II recall D-0309-2020, this FEI as the recalling firm | Oct 28, 2019 | 4 x 0.25 | 1 |
| Class II recall D-0083-2019, this FEI as the recalling firm | Oct 11, 2018 | 4 x 0.25 | 1 |
| Inspection classified VAI | Sep 16, 2016 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Aug 17, 2012 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Mar 21, 2011 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Feb 9, 2010 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Feb 9, 2010 | 10 years or older, so it adds no points | 0 |
| Class II recall D-357-2010, this FEI as the recalling firm | Jan 27, 2010 | 10 years or older, so it adds no points | 0 |
| Warning letter on FDA's dashboard, which does not show close-outs | Mar 30, 2009 | 10 years or older, so it adds no points | 0 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Inspection citations | Nov 16, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 16, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 16, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 13, 2026 | Newest record Nov 12, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Lannett Company, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Lannett Company, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Lannett Company, Inc.
- Location
- Philadelphia, PA (US)
- Source
- inspections